ARRY has been going down for too long since they they withdrawn their FDA application for its skin cancer drug binimetinib after poor P3 results.
Stock seems oversold atm. Yesterday's results were quite positive. May have a short squeeze.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款閱讀更多資訊。